Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: Acute Hepatitis C Virus Infection
• MONDO ID: (if available)
• Category: Infectious

Research Objectives

Please provide a comprehensive research report on Acute Hepatitis C Virus Infection covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: Acute Hepatitis C Virus (HCV) Infection (Infectious)

Executive summary

Acute (recently acquired) hepatitis C is the first ~6 months after HCV exposure, a period during which infection may spontaneously clear but still frequently progresses to chronic hepatitis C (persistent viremia >6 months). Diagnosis is challenging because most cases are asymptomatic and anti-HCV serology has a window period; nucleic acid testing (NAT) is therefore central. Current expert consensus in major guidance documents supports a “test-and-treat” approach (treat acute infection with standard DAA regimens rather than waiting for spontaneous clearance), while abbreviated short-course regimens (e.g., 6 weeks) are generally not recommended outside trials because of inferior outcomes. (fasano2024acutehepatitisc pages 1-2, liu2023acutehepatitisc pages 5-6, fasano2024acutehepatitisc pages 2-4, panel2023idsaguidelines pages 9-10)

Table: This table summarizes high-yield evidence for defining, diagnosing, and managing acute hepatitis C virus infection, including diagnostic windows, natural history, risk groups, and current guideline-based treatment. It is useful as a concise knowledge-base-ready abstraction anchored to the gathered evidence contexts.

1. Disease information

1.1 Overview / definition (current understanding)

• Acute / recently acquired HCV infection is generally defined as the first 6 months after initial exposure; chronic HCV infection is defined by persistence of viremia for >6 months. (fasano2024acutehepatitisc pages 1-2, fasano2024acutehepatitisc pages 4-5, liu2023acutehepatitisc pages 5-6)
• The term “acute hepatitis C” is used variably (biological vs clinical definitions are not completely standardized), and many incident infections are clinically silent. (fasano2024acutehepatitisc pages 4-5, liu2023acutehepatitisc pages 5-6)

1.2 Key identifiers and controlled vocabularies

• ICD-10: B17.1 = Acute hepatitis C. (macri2023acuteseverehepatitis pages 2-3)
• ICD-11: Not directly retrievable for acute hepatitis C from the available sources in this run; one GBD-methods paper indicates ICD-11 codes for chronic hepatitis C and sequelae (cirrhosis/HCC), but does not provide a stem code for acute infection. (bai2025globalregionaland pages 1-2)
• MeSH / MONDO: Not directly retrievable from the available sources in this run (no authoritative MeSH descriptor record or MONDO ID located in retrieved evidence). (fasano2024acutehepatitisc pages 1-2, fasano2024acutehepatitisc pages 2-4)

1.3 Synonyms / alternative names

• Acute hepatitis C
• Recent(ly) acquired HCV infection
• Incident HCV infection
• Early phase of HCV infection (fasano2024acutehepatitisc pages 1-2, fasano2024acutehepatitisc pages 4-5, fasano2024acutehepatitisc pages 2-4)

1.4 Evidence provenance (patient-level vs aggregated)

The information below is derived primarily from aggregated resources (reviews/guidelines, surveillance summaries, GBD analyses, and clinical trial registries), rather than individual EHR case series. (fasano2024acutehepatitisc pages 2-4, zou2024epidemiologyofacute pages 1-2, liu2023acutehepatitisc pages 3-5, NCT03818308 chunk 1)

2. Etiology

2.1 Disease causal factors

• Causative agent: Hepatitis C virus (HCV), a blood-borne, enveloped RNA virus; acute infection follows exposure and may progress to chronic infection with long-term liver disease. (zilouchian2025currentandfuture pages 1-3, fasano2024acutehepatitisc pages 1-2)

2.2 Risk factors

2.2.1 Transmission routes and high-risk populations

Major routes and groups consistently identified: * Parenteral exposure, especially people who inject drugs (PWID) and unsafe medical procedures. (liu2023acutehepatitisc pages 1-3, liu2023acutehepatitisc pages 5-6, fasano2024acutehepatitisc pages 1-2) * Sexual transmission is particularly important among men who have sex with men (MSM) and people living with HIV (PLWH), often linked to sexual risk behavior and recreational drug use. (fasano2024acutehepatitisc pages 1-2, fasano2024acutehepatitisc pages 2-4) * Additional at-risk groups include: intranasal illicit drug users, blood transfusion/transplant recipients before 1992, persons on long-term hemodialysis, and people ever incarcerated. (fasano2024acutehepatitisc pages 2-4)

Quantitative incidence estimates in key populations (examples): * In MSM: pooled HCV incidence in HIV-positive MSM ~8.46/1,000 person-years; in HIV-negative MSM on PrEP ~14.80/1,000 person-years (vs 0.12/1,000 person-years in HIV-negative MSM not on PrEP). (liu2023acutehepatitisc pages 3-5) * In PWID: incidence can be extremely high early after initiation of injecting (up to 133 per 100 person-years in the first year in young PWID, as summarized in a clinical review). (liu2023acutehepatitisc pages 3-5)

2.2.2 Host genetic and immunologic risk/clearance modifiers

A 2023 clinical update summarizes host factors associated with spontaneous clearance (SC) versus progression: * Higher likelihood of SC: female sex; white ethnicity; absence of HIV coinfection; HBV coinfection; IL28B/IFNL3 genotypes rs12979860 CC and rs8099917 TT; specific HLA class II alleles (DQB102, DQB103, DRB104, DRB111); strong HCV-specific T-cell responses; limited quasispecies diversity. (liu2023acutehepatitisc pages 5-6)

2.3 Protective factors

Evidence in the retrieved sources supports that protective factors largely overlap with predictors of spontaneous clearance: * IFNL3/IL28B favorable genotypes and certain HLA class II alleles increase odds of clearance in acute infection. (liu2023acutehepatitisc pages 5-6)

2.4 Gene–environment interactions

Evidence suggests host genotype interacts with immune context and exposure environment: * Sex and interferon-lambda genotype can shape intrahepatic antiviral gene networks and immune response patterns in HCV infection (with implications for outcome variability and response to therapy), highlighting a biologically plausible gene–environment/host–pathogen interaction framework. (toma2025hepatitiscvirus pages 1-2)

3. Phenotypes (clinical features)

3.1 Common clinical presentation

• Asymptomatic infection is common: ~80% of acute infections may be asymptomatic. (liu2023acutehepatitisc pages 5-6)
• Symptomatic acute hepatitis C occurs in a minority; one review reports ~20% symptomatic (fatigue, anorexia, nausea/vomiting, abdominal pain, jaundice). (fasano2024acutehepatitisc pages 4-5)
• Incubation period: ~2–20 weeks (typical ~7 weeks) in reviews. (sallam2024contemporaryinsightsinto pages 10-11)

3.2 Laboratory abnormalities and dynamics

• ALT elevation can be a key clue; supportive diagnostic criteria include ALT >5× ULN. (fasano2024acutehepatitisc pages 2-4)
• Viral kinetics: an early “pre-ramp-up” phase (2–14 days), “ramp-up” (8–10 days), then a “plateau” (45–68 days) has been described in a clinical update (relevant to early-diagnosis challenges). (liu2023acutehepatitisc pages 5-6)

3.3 Rare/severe manifestations

• Acute liver failure is rare in acute HCV, reported as <1% of cases in a 2024 review. (fasano2024acutehepatitisc pages 4-5)

3.4 Suggested HPO terms (mapping suggestions)

These are ontology mapping suggestions for knowledge-base use (not asserted as exhaustive): * Jaundice (HP:0000952) * Fatigue (HP:0012378) * Nausea (HP:0002018) * Vomiting (HP:0002013) * Abdominal pain (HP:0002027) * Elevated hepatic transaminases / Elevated alanine aminotransferase (often represented via “Abnormal liver function test”; lab-phenotype HPO mapping may vary by curation practice)

3.5 Quality-of-life impact

Direct, acute-phase QoL metrics (e.g., SF-36/EQ-5D) were not retrievable from the sources in this run; however, asymptomatic presentation is common, and symptomatic episodes can reduce functioning transiently (fatigue, nausea, jaundice). (fasano2024acutehepatitisc pages 4-5, liu2023acutehepatitisc pages 5-6)

4. Genetic / molecular information

4.1 Causal genes

Acute hepatitis C is not a Mendelian genetic disease; it is caused by HCV infection. Host genetics act mainly as modifiers of clearance and disease course. (liu2023acutehepatitisc pages 5-6)

4.2 Modifier genes / loci supported in retrieved evidence

• IFNL3 / IL28B polymorphisms (e.g., rs12979860, rs8099917) are associated with spontaneous clearance likelihood. (liu2023acutehepatitisc pages 5-6)
• HLA class II alleles (e.g., DQB102, DQB103, DRB104, DRB111) are associated with spontaneous clearance in summarized evidence. (liu2023acutehepatitisc pages 5-6)

4.3 Epigenetics and chromosomal abnormalities

Not specifically retrievable for acute infection from the sources in this run.

5. Environmental information

5.1 Environmental / healthcare-associated factors

• Unsafe medical procedures (e.g., unsafe injections, invasive procedures) remain important in some regions; a clinical update emphasizes ongoing healthcare-associated transmission in some WHO regions. (liu2023acutehepatitisc pages 1-3)

5.2 Lifestyle / behavioral factors

• Injection drug use–related behaviors (shared syringes and preparation equipment, frequent injections, multiple injecting partners) are highlighted as major drivers of transmission. (liu2023acutehepatitisc pages 5-6)

5.3 Infectious agent

• Hepatitis C virus is the relevant infectious agent. (zilouchian2025currentandfuture pages 1-3)

6. Mechanism / pathophysiology

6.1 Causal chain (high-level)

1. Exposure and entry: Blood-borne (primarily) exposure introduces HCV; viremia becomes detectable early. (fasano2024acutehepatitisc pages 2-4, liu2023acutehepatitisc pages 5-6)
2. Early replication and innate/adaptive response: Viral RNA rises rapidly; liver inflammation and ALT elevation may follow. (liu2023acutehepatitisc pages 5-6)
3. Outcome bifurcation (clearance vs persistence): A subset clears infection spontaneously (linked to robust CD4+/CD8+ responses and favorable host genetics); the remainder progresses to chronic infection. (liu2023acutehepatitisc pages 5-6, fasano2024acutehepatitisc pages 4-5)

6.2 Immune system involvement (evidence-based highlights)

• Clearance is associated with broad, multi-specific CD4+ and CD8+ T-cell responses; maintenance of virus-specific CD4+ responses and HCV-specific CD8+ T cells correlate with viral clearance in summarized evidence. (fasano2024acutehepatitisc pages 4-5, fasano2024acutehepatitisc pages 8-10)

6.3 Suggested GO biological process terms (mechanism-oriented)

Mapping suggestions for knowledge-base annotation: * Type I interferon signaling pathway (GO:0060337) / response to virus (GO:0009615) * T cell activation (GO:0042110) * antigen processing and presentation (e.g., GO:0019882)

6.4 Suggested Cell Ontology (CL) terms (cell types)

Mapping suggestions: * Hepatocyte (CL:0000182) * CD4-positive, alpha-beta T cell (CL:0000624) * CD8-positive, alpha-beta T cell (CL:0000625)

6.5 Molecular profiling / omics

• Intrahepatic transcriptional responses vary by host factors; a liver transcriptomics study in HCV identified sex- and IFNL4/IL28B-associated differences in antiviral modules (supporting biologic heterogeneity relevant to outcomes and therapy response). (toma2025hepatitiscvirus pages 1-2)

7. Anatomical structures affected

7.1 Organ/system level

• Primary organ: liver (acute hepatitis). (fasano2024acutehepatitisc pages 4-5)

7.2 Suggested UBERON term

• Liver (UBERON:0002107)

8. Temporal development (natural history)

8.1 Onset and staging

• Viremia detectable by NAT within ~1–2 weeks after exposure; seroconversion typically 4–12 weeks. (fasano2024acutehepatitisc pages 2-4)
• Acute phase is generally defined as ≤6 months post-exposure. (liu2023acutehepatitisc pages 5-6)

8.2 Progression and remission

• Spontaneous clearance occurs in a minority (estimates vary by population and definition), while a large fraction progresses to chronic infection; one review emphasizes ~50–70% progress to chronic infection (viremia >6 months). (fasano2024acutehepatitisc pages 4-5)

9. Inheritance and population

9.1 Epidemiology (recent statistics)

Global burden and incidence (GBD/WHO summaries): * A 2023 clinical update summarizes WHO estimates of ~1.5 million newly acquired HCV infections in 2019, with regional distribution noted (e.g., Eastern Mediterranean ~470k, Europe ~300k). (liu2023acutehepatitisc pages 3-5) * A 2024 GBD-based analysis of reproductive-age women reported that global incidences of acute hepatitis C increased 46.45% from 1990 to 2019 in this demographic. (zou2024epidemiologyofacute pages 1-2)

Europe (surveillance context): * EU/EEA crude reported hepatitis C rate in 2022 was about 6.2 per 100,000 (23,273 cases), with a COVID-era dip and 2022 rebound. (simao2024hepatitiscvirus pages 1-2)

Key populations (PWID): * In 25 European countries, civil-society monitoring notes HCV seroprevalence among PWID ranging 16%–86% and identifies PWID as the main source of new cases. (maticic2024howfarare pages 1-2)

9.2 Demographics

• Males accounted for about 54.6% of new infections in 2019 in summarized global estimates. (liu2023acutehepatitisc pages 3-5)

10. Diagnostics

10.1 Diagnostic concepts and definitions (acute vs chronic)

• Acute diagnosis is most robust when there is HCV RNA positivity with negative anti-HCV (window period) or documented anti-HCV seroconversion within 6 months. (fasano2024acutehepatitisc pages 2-4)
• Anti-HCV positive + HCV RNA positive confirms active infection but does not distinguish acute from chronic without prior testing history. (fasano2024acutehepatitisc pages 2-4)

10.2 Testing windows and algorithms (key data)

• HCV RNA detectability: ~1–2 weeks post-exposure. (fasano2024acutehepatitisc pages 2-4, liu2023acutehepatitisc pages 5-6)
• Anti-HCV antibodies: typically 4–12 weeks, and may be delayed/absent in PLWH, hemodialysis, and transplant recipients—necessitating RNA-based testing. (fasano2024acutehepatitisc pages 2-4)

10.3 Diagnostic algorithm (visual)

Figure evidence for the acute HCV diagnostic algorithm is available here: (fasano2024acutehepatitisc media 039e3907)

10.4 Emerging / improved diagnostics (2023–2024 emphasis)

• A 2024 clinical microbiology study evaluated a dual antibody/core antigen assay (Roche Elecsys HCV Duo) vs standard antibody + NAAT algorithms, noting fourth-generation Ab/Ag assays can shorten the diagnostic window by 2.2–21.9 days vs Ab-only assays; NAAT still detects some Ab−/RNA+ infections missed by serology/Ag. (bui2024comparisonofa pages 2-4, bui2024comparisonofa pages 1-2)

10.5 Differential diagnosis

Acute hepatitis C diagnostic criteria explicitly include exclusion of other causes of acute hepatitis (HAV, HBV, HDV in chronic HBV, autoimmune hepatitis). (fasano2024acutehepatitisc pages 2-4)

11. Outcome / prognosis

11.1 Clearance vs chronicity

• Progression to chronic infection is common; multiple sources report ranges (e.g., 50–70% progressing to chronic, with spontaneous clearance in the remainder). (fasano2024acutehepatitisc pages 4-5, sallam2024contemporaryinsightsinto pages 10-11, liu2023acutehepatitisc pages 5-6)

11.2 Complications

• Acute liver failure is rare (<1%), but untreated chronic infection drives long-term fibrosis/cirrhosis/HCC risk (contextualized in reviews). (fasano2024acutehepatitisc pages 4-5, zilouchian2025currentandfuture pages 1-3)

12. Treatment

12.1 Current guideline position (expert consensus)

• AASLD–IDSA 2023 guidance: treat confirmed acute HCV infection the same as chronic infection and do not wait for spontaneous clearance (“test-and-treat”). (panel2023idsaguidelines pages 9-10)
• The guidance does not recommend abbreviated 6-week DAA courses for acute infection because trials showed inferior responses. (panel2023idsaguidelines pages 9-10)

12.2 Simplified pangenotypic regimens used in practice (including acute)

A 2024 article summarizing AASLD–IDSA 2023 simplified guidance states that the following regimens are suitable for acute or chronic treatment-naive infection under simplified pathways (with standard exclusions such as pregnancy and decompensated cirrhosis): * Glecaprevir/pibrentasvir (G/P): 8 weeks * Sofosbuvir/velpatasvir (SOF/VEL): 12 weeks (pan2024revampinghepatitisc pages 1-2, pan2024revampinghepatitisc pages 2-4)

12.3 Clinical trials and real-world implementation examples (NCT identifiers)

Recent/important acute-HCV DAA trials in ClinicalTrials.gov (illustrative, not exhaustive): * NCT04903626 (AbbVie): Phase 3, single-arm, G/P 8 weeks, n=286, completed 2024-09-17; primary endpoint SVR12. (NCT04903626 chunk 1) * NCT04042740 (ACTG PURGE-C): Phase 2, G/P 4 weeks, n=45, completed; SVR12 primary endpoint; results posted July 2024. (NCT04042740 chunk 1) * NCT03818308 (HepNet-aHCV-V): Phase 2, SOF/VEL 8 weeks, n=20, completed. (NCT03818308 chunk 1) * NCT02128217 (SWIFT-C): Phase 1, HIV-coinfected adults; sofosbuvir-based regimens (SOF+RBV 12 weeks; LDV/SOF 8 weeks), n=44. (NCT02128217 chunk 1)

12.4 MAXO (Medical Action Ontology) term suggestions

Mapping suggestions for curation: * Direct-acting antiviral therapy (MAXO term selection depends on local MAxO release; suggested concept: “antiviral therapy” / “direct-acting antiviral therapy”) * HCV RNA testing (diagnostic action) * Harm-reduction intervention (preventive action)

13. Prevention

13.1 Primary prevention

• Universal precautions, safe injection practices, and harm reduction are repeatedly emphasized in clinical reviews for reducing acute transmission. (liu2023acutehepatitisc pages 1-3, liu2023acutehepatitisc pages 5-6)

13.2 Secondary prevention (screening / early detection)

• AASLD–IDSA-aligned summaries emphasize universal one-time adult screening and repeat/annual screening in high-risk groups, with reflex HCV RNA after antibody testing. (pan2024revampinghepatitisc pages 1-2)

13.3 Vaccine landscape

• No prophylactic HCV vaccine is currently available, and major scientific obstacles include HCV genetic diversity and limited animal models. (liu2023acutehepatitisc pages 1-3, fasano2024acutehepatitisc pages 7-8)

14. Other species / natural disease

Not specifically addressed in retrieved sources for acute infection in this run. (The broader literature includes non-human primate and humanized mouse systems for HCV, but authoritative citations were not retrieved here.)

15. Model organisms

Not specifically addressed in retrieved sources for acute infection in this run.

Notes on evidence gaps (transparent limitations)

• MONDO ID and MeSH descriptor IDs for acute hepatitis C were not found in the retrieved corpus for this run; these would normally be sourced from MONDO/MeSH browser records rather than primary clinical studies. (fasano2024acutehepatitisc pages 2-4)
• ICD-11 acute hepatitis C stem code was not located in the retrieved evidence; ICD-11 was referenced primarily in the context of chronic/sequelae coding in a GBD methods paper. (bai2025globalregionaland pages 1-2)

Key sources (with URLs and publication dates)

• Liu & Kao. Clinical and Molecular Hepatology. July 2023. “Acute hepatitis C virus infection: clinical update and remaining challenges.” https://doi.org/10.3350/cmh.2022.0349 (liu2023acutehepatitisc pages 1-3)
• Fasano et al. Viruses. Nov 2024. “Acute Hepatitis C: Current Status and Future Perspectives.” https://doi.org/10.3390/v16111739 (fasano2024acutehepatitisc pages 1-2)
• Pan & Park. Translational Gastroenterology and Hepatology. Apr 2024. “Revamping hepatitis C global eradication efforts: towards simplified and enhanced screening, prevention, and treatment.” https://doi.org/10.21037/tgh-23-104 (pan2024revampinghepatitisc pages 1-2)
• Bui et al. Journal of Clinical Microbiology. Oct 2024. “Comparison of a dual antibody and antigen HCV immunoassay to standard of care algorithmic testing.” https://doi.org/10.1128/jcm.00832-24 (bui2024comparisonofa pages 2-4)
• Zou et al. Journal of Global Health. Apr 2024. “Epidemiology of acute hepatitis C … in reproductive-age women, 1990–2019 (GBD).” https://doi.org/10.7189/jogh.14.04077 (zou2024epidemiologyofacute pages 1-2)

References

1. (fasano2024acutehepatitisc pages 1-2): Massimo Fasano, Francesco Ieva, Marianna Ciarallo, Bruno Caccianotti, and Teresa Antonia Santantonio. Acute hepatitis c: current status and future perspectives. Viruses, 16:1739, Nov 2024. URL: https://doi.org/10.3390/v16111739, doi:10.3390/v16111739. This article has 21 citations.

2. (liu2023acutehepatitisc pages 5-6): Chen-Hua Liu and Jia-Horng Kao. Acute hepatitis c virus infection: clinical update and remaining challenges. Clinical and Molecular Hepatology, 29:623-642, Jul 2023. URL: https://doi.org/10.3350/cmh.2022.0349, doi:10.3350/cmh.2022.0349. This article has 93 citations.

3. (fasano2024acutehepatitisc pages 2-4): Massimo Fasano, Francesco Ieva, Marianna Ciarallo, Bruno Caccianotti, and Teresa Antonia Santantonio. Acute hepatitis c: current status and future perspectives. Viruses, 16:1739, Nov 2024. URL: https://doi.org/10.3390/v16111739, doi:10.3390/v16111739. This article has 21 citations.

4. (panel2023idsaguidelines pages 9-10): AIHCVG Panel. Idsa guidelines. Unknown journal, 2023.

5. (fasano2024acutehepatitisc pages 4-5): Massimo Fasano, Francesco Ieva, Marianna Ciarallo, Bruno Caccianotti, and Teresa Antonia Santantonio. Acute hepatitis c: current status and future perspectives. Viruses, 16:1739, Nov 2024. URL: https://doi.org/10.3390/v16111739, doi:10.3390/v16111739. This article has 21 citations.

6. (zilouchian2025currentandfuture pages 4-6): Hussein Zilouchian, Omair Faqah, Md Alamgir Kabir, Dennis Gross, Rachel Pan, Shane Shaifman, Muhammad Awais Younas, Muhammad Abdul Haseeb, Emmanuel Thomas, and Waseem Asghar. Current and future diagnostics for hepatitis c virus infection. Chemosensors, 13:31, Jan 2025. URL: https://doi.org/10.3390/chemosensors13020031, doi:10.3390/chemosensors13020031. This article has 7 citations.

7. (bui2024comparisonofa pages 1-2): Tina I. Bui, Abigail P. Brown, Meghan Brown, Sydney Lawless, Brittany Roemmich, Neil W. Anderson, and Christopher W. Farnsworth. Comparison of a dual antibody and antigen hcv immunoassay to standard of care algorithmic testing. Journal of Clinical Microbiology, Oct 2024. URL: https://doi.org/10.1128/jcm.00832-24, doi:10.1128/jcm.00832-24. This article has 7 citations and is from a peer-reviewed journal.

8. (galli2025hcvserologyan pages 12-13): Claudio Galli and M. Plebani. Hcv serology: an unfinished agenda. Clinical chemistry and laboratory medicine, Aug 2025. URL: https://doi.org/10.1515/cclm-2025-0501, doi:10.1515/cclm-2025-0501. This article has 0 citations and is from a peer-reviewed journal.

9. (sallam2024contemporaryinsightsinto pages 10-11): Malik Sallam and Roaa Khalil. Contemporary insights into hepatitis c virus: a comprehensive review. Microorganisms, 12:1035, May 2024. URL: https://doi.org/10.3390/microorganisms12061035, doi:10.3390/microorganisms12061035. This article has 63 citations.

10. (fasano2024acutehepatitisc pages 7-8): Massimo Fasano, Francesco Ieva, Marianna Ciarallo, Bruno Caccianotti, and Teresa Antonia Santantonio. Acute hepatitis c: current status and future perspectives. Viruses, 16:1739, Nov 2024. URL: https://doi.org/10.3390/v16111739, doi:10.3390/v16111739. This article has 21 citations.

11. (kaur2025anexhaustiveupdate pages 4-6): Kulvinder Kochar Kaur, Gautam Nand Allahbadia, and Mandeep Singh. An exhaustive update on eradication of hepatitis c virus (hcv) with the objective of eradicating chronic hepatitis by 2030- a narrative review. Journal of Infectious Diseases & Treatments, pages 1-21, Dec 2025. URL: https://doi.org/10.61440/jidt.2025.v3.48, doi:10.61440/jidt.2025.v3.48. This article has 0 citations.

12. (liu2023acutehepatitisc pages 1-3): Chen-Hua Liu and Jia-Horng Kao. Acute hepatitis c virus infection: clinical update and remaining challenges. Clinical and Molecular Hepatology, 29:623-642, Jul 2023. URL: https://doi.org/10.3350/cmh.2022.0349, doi:10.3350/cmh.2022.0349. This article has 93 citations.

13. (panel2023idsaguidelines pages 4-5): AIHCVG Panel. Idsa guidelines. Unknown journal, 2023.

14. (fasano2024acutehepatitisc pages 5-7): Massimo Fasano, Francesco Ieva, Marianna Ciarallo, Bruno Caccianotti, and Teresa Antonia Santantonio. Acute hepatitis c: current status and future perspectives. Viruses, 16:1739, Nov 2024. URL: https://doi.org/10.3390/v16111739, doi:10.3390/v16111739. This article has 21 citations.

15. (pan2024revampinghepatitisc pages 2-4): Calvin Q. Pan and James S. Park. Revamping hepatitis c global eradication efforts: towards simplified and enhanced screening, prevention, and treatment. Translational Gastroenterology and Hepatology, 9:30-30, Apr 2024. URL: https://doi.org/10.21037/tgh-23-104, doi:10.21037/tgh-23-104. This article has 5 citations and is from a peer-reviewed journal.

16. (pan2024revampinghepatitisc pages 1-2): Calvin Q. Pan and James S. Park. Revamping hepatitis c global eradication efforts: towards simplified and enhanced screening, prevention, and treatment. Translational Gastroenterology and Hepatology, 9:30-30, Apr 2024. URL: https://doi.org/10.21037/tgh-23-104, doi:10.21037/tgh-23-104. This article has 5 citations and is from a peer-reviewed journal.

17. (liu2023acutehepatitisc pages 12-13): Chen-Hua Liu and Jia-Horng Kao. Acute hepatitis c virus infection: clinical update and remaining challenges. Clinical and Molecular Hepatology, 29:623-642, Jul 2023. URL: https://doi.org/10.3350/cmh.2022.0349, doi:10.3350/cmh.2022.0349. This article has 93 citations.

18. (NCT03818308 chunk 1): Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir. Hannover Medical School. 2019. ClinicalTrials.gov Identifier: NCT03818308

19. (NCT02634008 chunk 1): Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P. Kirby Institute. 2016. ClinicalTrials.gov Identifier: NCT02634008

20. (NCT04903626 chunk 1): Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB). AbbVie. 2021. ClinicalTrials.gov Identifier: NCT04903626

21. (NCT04042740 chunk 1): Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. 2019. ClinicalTrials.gov Identifier: NCT04042740

22. (macri2023acuteseverehepatitis pages 2-3): Jennifer Macri, Vanessa Morton, Megan Hame, Pierre-Luc Trépanier, and Marina Salvadori. Acute severe hepatitis of unknown origin in children in canada. Canada Communicable Disease Report, 49:256-262, Jun 2023. URL: https://doi.org/10.14745/ccdr.v49i06a02, doi:10.14745/ccdr.v49i06a02. This article has 3 citations.

23. (bai2025globalregionaland pages 1-2): Junzhu Bai, Hengliang Lv, Longhao Wang, Shumeng You, Dan Liu, Lilin Wang, Yuanyong Xu, Junfeng Lu, and Wenyi Zhang. Global, regional, and national burden of hepatitis c from 1990 to 2021 and projections until 2030. BMC Infectious Diseases, Dec 2025. URL: https://doi.org/10.1186/s12879-025-12396-y, doi:10.1186/s12879-025-12396-y. This article has 0 citations and is from a peer-reviewed journal.

24. (zou2024epidemiologyofacute pages 1-2): Yanzheng Zou, Ming Yue, Xiangyu Ye, Yifan Wang, Xinyan Ma, Amei Zhang, Xueshan Xia, Hongbo Chen, Rongbin Yu, Sheng Yang, and Peng Huang. Epidemiology of acute hepatitis c and hepatitis c virus-related cirrhosis in reproductive-age women, 1990–2019: an analysis of the global burden of disease study. Journal of Global Health, Apr 2024. URL: https://doi.org/10.7189/jogh.14.04077, doi:10.7189/jogh.14.04077. This article has 11 citations and is from a peer-reviewed journal.

25. (liu2023acutehepatitisc pages 3-5): Chen-Hua Liu and Jia-Horng Kao. Acute hepatitis c virus infection: clinical update and remaining challenges. Clinical and Molecular Hepatology, 29:623-642, Jul 2023. URL: https://doi.org/10.3350/cmh.2022.0349, doi:10.3350/cmh.2022.0349. This article has 93 citations.

26. (zilouchian2025currentandfuture pages 1-3): Hussein Zilouchian, Omair Faqah, Md Alamgir Kabir, Dennis Gross, Rachel Pan, Shane Shaifman, Muhammad Awais Younas, Muhammad Abdul Haseeb, Emmanuel Thomas, and Waseem Asghar. Current and future diagnostics for hepatitis c virus infection. Chemosensors, 13:31, Jan 2025. URL: https://doi.org/10.3390/chemosensors13020031, doi:10.3390/chemosensors13020031. This article has 7 citations.

27. (toma2025hepatitiscvirus pages 1-2): Daniela Toma, Lucreția Anghel, Diana Patraș, and A. Ciubara. Hepatitis c virus: epidemiological challenges and global strategies for elimination. Viruses, Jul 2025. URL: https://doi.org/10.3390/v17081069, doi:10.3390/v17081069. This article has 18 citations.

28. (fasano2024acutehepatitisc pages 8-10): Massimo Fasano, Francesco Ieva, Marianna Ciarallo, Bruno Caccianotti, and Teresa Antonia Santantonio. Acute hepatitis c: current status and future perspectives. Viruses, 16:1739, Nov 2024. URL: https://doi.org/10.3390/v16111739, doi:10.3390/v16111739. This article has 21 citations.

29. (simao2024hepatitiscvirus pages 1-2): Margarida Simão and Cristina Gonçalves. Hepatitis c virus infection in europe. Pathogens, 13:841, Sep 2024. URL: https://doi.org/10.3390/pathogens13100841, doi:10.3390/pathogens13100841. This article has 7 citations.

30. (maticic2024howfarare pages 1-2): Mojca Maticic, J. Cernosa, C. Loboda, J. Tamse, R. Rigoni, E. Duffell, I. Indave, R. Zimmermann, L. Darragh, J. Moura, A. Leicht, T. Windelinckx, M. Jauffret-Roustide, K. Schiffer, and T. Tammi. How far are we? assessing progress in hepatitis c response towards the who 2030 elimination goals by the civil society monitoring in 25 european countries, period 2020 to 2023. Harm Reduction Journal, Nov 2024. URL: https://doi.org/10.1186/s12954-024-01115-6, doi:10.1186/s12954-024-01115-6. This article has 3 citations and is from a peer-reviewed journal.

31. (fasano2024acutehepatitisc media 039e3907): Massimo Fasano, Francesco Ieva, Marianna Ciarallo, Bruno Caccianotti, and Teresa Antonia Santantonio. Acute hepatitis c: current status and future perspectives. Viruses, 16:1739, Nov 2024. URL: https://doi.org/10.3390/v16111739, doi:10.3390/v16111739. This article has 21 citations.

32. (bui2024comparisonofa pages 2-4): Tina I. Bui, Abigail P. Brown, Meghan Brown, Sydney Lawless, Brittany Roemmich, Neil W. Anderson, and Christopher W. Farnsworth. Comparison of a dual antibody and antigen hcv immunoassay to standard of care algorithmic testing. Journal of Clinical Microbiology, Oct 2024. URL: https://doi.org/10.1128/jcm.00832-24, doi:10.1128/jcm.00832-24. This article has 7 citations and is from a peer-reviewed journal.

33. (NCT02128217 chunk 1): Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. 2014. ClinicalTrials.gov Identifier: NCT02128217

1. Disease Information

Overview

Acute Hepatitis C Virus Infection is defined as the first 6 months following initial HCV exposure and infection, characterized by detectable HCV RNA in the blood, with or without symptoms, and prior to the establishment of chronic infection. HCV is a small, enveloped, positive-sense single-stranded RNA virus belonging to the family Flaviviridae, genus Hepacivirus. The virus has a 9.6 kb genome encoding a single polyprotein of approximately 3,000 amino acids, which is processed into 10 structural (Core, E1, E2) and non-structural (p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B) proteins (PMID: 10726057).

Key Identifiers

Synonyms and Alternative Names

• Acute HCV infection
• Acute hepatitis C (AHC)
• Recently acquired hepatitis C
• Recent HCV infection (duration of infection <12 months)
• Non-A, non-B hepatitis (historical term)

Information Sources

The information in this report is derived from aggregated disease-level resources including systematic reviews, meta-analyses, genome-wide association studies, large clinical cohorts, phase III clinical trials, and Global Burden of Disease (GBD) 2021 data, supplemented by individual patient-level data from prospective observational studies and controlled clinical trials.

2. Etiology

Disease Causal Factors

Primary Cause: Infection with Hepatitis C Virus (HCV; NCBI Taxonomy ID: 11103), a blood-borne pathogen. HCV is an enveloped, positive-sense, single-stranded RNA virus of the family Flaviviridae. There are 8 major genotypes (1-8) and more than 90 subtypes with distinct geographic distributions.

Transmission routes: - Injection drug use (IDU): The predominant mode of transmission globally, accounting for >60% of new infections in high-income countries. Equipment sharing (needles, syringes, cookers, cotton filters) is the primary risk behavior (PMID: 25270261). - Unsafe medical procedures: Nosocomial transmission through contaminated blood products, inadequately sterilized medical equipment, and dialysis. This is a major route in low- and middle-income countries (PMID: 12227687). - Sexual transmission: Particularly among HIV-positive MSM, where mucosal trauma during receptive anal intercourse and fisting creates direct blood-to-blood contact (PMID: 21408083). - Vertical transmission: Mother-to-child transmission occurs in 3-5% of pregnancies with HCV-positive mothers, rising to ~19.4% with HIV co-infection (PMID: 24187446). - Occupational exposure: Healthcare workers exposed to HCV-contaminated needlesticks have a 0.5% transmission risk per exposure (PMID: 18824553).

Risk Factors

Genetic Risk Factors

Environmental and Behavioral Risk Factors

• Injection drug use: Strongest behavioral risk factor; HCV seroprevalence among PWID ranges from 40-90% in various settings (PMID: 28652072)
• HIV co-infection: Reduces spontaneous clearance rate from ~30-50% to ~15% (PMID: 21139063)
• Male sex: Males have consistently higher disease burden (PMID: 41882797)
• Age: Bimodal age pattern with peaks in early childhood (0-4 years, vertical transmission) and older adults (>95 years, historical exposures) (PMID: 42007346)
• Alcohol consumption: Accelerates liver disease progression via competition with retinol metabolism through the ADH-ALDH pathway (PMID: 26638120)
• High-risk sexual behavior: Receptive fisting, sex-associated rectal bleeding, group sex, and sharing snorting equipment in MSM populations (PMID: 21408083)
• Incarceration: Disproportionately high HCV prevalence in carceral settings with limited access to testing and treatment (PMID: 41651702)

Protective Factors

Genetic Protective Factors

Environmental Protective Factors

• Female sex: Independently associated with spontaneous clearance (OR=2.39, P=0.007) (PMID: 24445571)
• Symptomatic/icteric presentation: Jaundice is associated with spontaneous clearance (OR=3.54, P=0.001), reflecting a vigorous immune response (PMID: 24445571)
• Harm reduction programs: Needle/syringe exchange programs and opioid substitution therapy reduce transmission risk (PMID: 34051065)

Gene-Environment Interactions

The interaction between IFNL3/IFNL4 genotype and viral genotype modulates disease outcome. IFN-lambda-4 exerts selective pressure across the viral proteome, with different HCV genotypes adapting differentially to IFN-lambda polymorphism (PMID: 31478832). Alcohol consumption competes with retinol for the ADH-ALDH metabolic pathway, reducing retinoic acid production and consequently attenuating ISG expression — a critical innate antiviral defense in hepatocytes (PMID: 26638120). Different individuals resolve HCV infection using discrete, non-interacting immunological pathways influenced by viral genotype: IFNL3 CC is protective in HCV genotype 1, while KIR2DL3:HLA-C1 is protective in HCV genotype 2/3 (PMID: 26381047).

3. Phenotypes

Symptoms and Clinical Signs

Laboratory Abnormalities

Phenotype Characteristics

• Age of onset: Any age; most commonly adult-onset (peak incidence 25-40 years); bimodal age pattern globally with peaks in early childhood and elderly (PMID: 42007346)
• Symptom severity: Predominantly mild or subclinical; fulminant hepatic failure is exceedingly rare (<1%)
• Symptom progression: Self-limited in those who clear; transition to chronicity is gradual and often clinically silent
• Quality of life impact: Acute phase may cause significant anxiety and reduced well-being during the waiting period for HCV status determination; healthcare workers exposed to HCV experience documented quality of life deterioration during follow-up (PMID: 18824553)

4. Genetic/Molecular Information

Host Genetic Determinants (Not Causal Genes, but Outcome Modifiers)

As an infectious disease, acute HCV has no "causal genes" in the traditional sense. However, host genetic variation profoundly influences disease outcome:

IFNL3/IFNL4 Locus (Chromosome 19q13.2): The IFNL3 (IL28B) gene (HGNC:18365) encodes interferon lambda 3. The nearby IFNL4 gene (HGNC:51362) produces IFN-lambda-4 from the ancestral allele. The rs12979860 C/T polymorphism near IFNL3 is the strongest single genetic predictor of spontaneous HCV clearance. The CC genotype confers a dramatically higher probability of clearance: "IL-28B-CC (odds ratio (OR) 14.22; P<0.0001)...were independently associated with spontaneous clearance" (PMID: 24445571).

Paradoxically, "individuals with the ancestral IFNlambda4 allele capable of producing a fully active IFNlambda4 are paradoxically not able to clear HCV in the acute phase and develop chronic hepatitis C (CHC) with more than 90% probability" (PMID: 27641986). The mechanism appears to involve constitutive ISG activation that renders cells refractory to further IFN stimulation.

HLA Locus: "HLA-A02:01 and DRB111:01 might be associated with the host capacity to clear HCV independent of IL28B, which suggesting that the innate and adaptive immune responses both play an important role in the control of HCV" (PMID: 27511600).

miR-122 Expression: Hepatic miR-122 expression is higher in patients with the IFNL3 CC genotype and is reduced during advanced fibrosis stages. miR-122 stimulates HCV replication in vitro but its higher expression in CC carriers paradoxically associates with viral clearance, suggesting complex regulation of the innate immune response (PMID: 24672032).

Viral Genetic Factors

HCV Genotypes: 8 major genotypes with distinct geographic distributions: - Genotype 1 (1a, 1b): Most prevalent globally (~46% of infections) - Genotype 3: Second most common (~22%), associated with steatosis - Genotype 4: Predominant in Middle East/North Africa - Genotype 2: Common in West Africa, Japan - Genotypes 5-8: More restricted distributions

Epigenetic Information

HCV infection alters host epigenetic patterns, including DNA methylation and miRNA expression. IFNL3 CT/TT carriers show reduced hepatic miR-122 expression, and miR-122 decreases with advancing fibrosis (Metavir F3/F4 vs. F1/F2, P=0.01) (PMID: 24672032). IFN-lambda-4 exerts selective pressure across the viral genome, influencing amino acid variation across the entire viral polyprotein and modulating viral load and dinucleotide proportions (PMID: 31478835).

5. Environmental Information

Infectious Agent

• Pathogen: Hepatitis C Virus (HCV)
• Taxonomy: NCBI Taxonomy ID 11103; Family Flaviviridae, Genus Hepacivirus, Species Hepacivirus hominis
• Genome: Positive-sense single-stranded RNA, ~9.6 kb
• Genotypes: 8 major genotypes, >90 subtypes
• CHEBI: CHEBI:59524 (hepatitis C virus particle)

Lifestyle Factors

• Injection drug use: The dominant transmission route in most high-income countries; HCV prevalence among PWID ranges from 40-90% (PMID: 28652072; PMID: 11440409)
• Alcohol consumption: Does not cause acute HCV but markedly accelerates progression to liver disease; ethanol competes with retinol for the ADH-ALDH pathway, reducing retinoic acid-mediated ISG expression (PMID: 26638120)
• High-cholesterol diet: Promotes steatohepatitis and tumorigenesis in HCV core transgenic mice (PMID: 31004178)
• Snorting drugs: Sharing intranasal drug equipment in group settings is an independent risk factor for HCV transmission among MSM (PMID: 21408083)

6. Mechanism / Pathophysiology

Molecular Pathways and Causal Chain

The pathophysiology of acute HCV infection proceeds through a defined sequence of events:

Step 1: Viral Entry (Upstream) HCV enters hepatocytes through a complex, multi-step process requiring sequential engagement of multiple host factors: 1. Initial attachment to heparan sulfate proteoglycans (HSPGs) and low-density lipoprotein receptor (LDLR) 2. Binding to Scavenger Receptor class B type I (SR-BI/SCARB1) — "SR-BI was an indispensable factor for 1b genotype HCV adsorption" (PMID: 34565156) 3. Interaction with tetraspanin CD81 4. Lateral translocation to tight junctions for engagement with Claudin-1 (CLDN1) and Occludin (OCLN) (PMID: 32268133; PMID: 31427285) 5. EGFR co-factor signaling, with ADAM10 sheddase activity supporting entry through EGFR transactivation (PMID: 37967063) 6. Clathrin-mediated endocytosis and pH-dependent fusion with endosomal membranes

GO terms: GO:0046718 (viral entry into host cell); GO:0019065 (viral genome replication)

Step 2: Viral Replication and Innate Immune Evasion Following uncoating, the positive-sense RNA genome serves as both mRNA for polyprotein translation and template for replication. Key enzymes include: - NS5B RNA-dependent RNA polymerase (the catalytic engine of replication) - NS3/4A serine protease (polyprotein processing and immune evasion) - NS3 NTPase/RNA helicase (genome unwinding)

The NS3/4A protease plays a dual role — it is essential for viral polyprotein processing and simultaneously cleaves host innate immune adaptor proteins: "the HCV NS3/4A protease can efficiently cleave and inactivate two important signalling molecules in the sensory pathways that react to HCV pathogen-associated molecular patterns (PAMPs) to induce IFNs, i.e., the mitochondrial anti-viral signalling protein (MAVS) and the Toll-IL-1 receptor-domain-containing adaptor-inducing IFN-beta (TRIF)" (PMID: 25443342).

GO terms: GO:0039503 (suppression by virus of host innate immune response); GO:0006508 (proteolysis)

Step 3: Innate Immune Response Despite viral evasion, the innate immune system mounts a response: - Pattern recognition receptors (RIG-I, TLR3, TLR7) detect viral RNA - Type III interferons (IFN-lambda) are the predominant antiviral cytokines in hepatocytes - NK cells are activated and altered in both acute and chronic HCV infection, with KIR receptor diversity influencing outcome (PMID: 26483779) - ISG induction occurs but may be paradoxically persistent in those progressing to chronicity

Cell types involved: Hepatocytes (CL:0000182), Kupffer cells (CL:0000091), NK cells (CL:0000623), dendritic cells (CL:0000451), liver sinusoidal endothelial cells (CL:0019031)

Step 4: Adaptive Immune Response (Determines Outcome) - Multi-specific CD4+ and CD8+ T-cell responses are critical for clearance (OR=11.66, P<0.0001 for multispecific T-cell responses and spontaneous clearance) (PMID: 24445571) - HLA class I (A02:01) and class II (DRB111:01) alleles independently predict clearance, confirming roles for both CD8+ cytotoxic and CD4+ helper T cells (PMID: 27511600) - Antibody responses develop but are not sufficient for clearance; neutralizing antibodies are often delayed and strain-specific

GO terms: GO:0002250 (adaptive immune response); GO:0042110 (T cell activation)

Step 5: Resolution or Chronicity - Clearance (~30-50%): Vigorous, broadly targeted, multi-specific T-cell response; favorable IFNL3 genotype; rapid HCV RNA decline (>2.5 log10 drop within 8 weeks) - Chronicity (~50-70%): T-cell exhaustion, viral escape mutations, constitutive but ineffective ISG activation, and persistent low-grade hepatic inflammation

Immune System Involvement

The immune response in acute HCV is central to disease pathogenesis:

• Innate immunity: "Spontaneous clearance of HCV infection is associated with a prompt induction of innate immunity generated in an infected host" (PMID: 30909456). Despite this, HCV evades through NS3/4A cleavage of MAVS and TRIF.
• Adaptive immunity: "approximately 25% of acute infection cases result in spontaneous clearance. The exact immune mechanisms that govern the infection outcome remain largely unknown; recent discoveries suggest that the innate immune system facilitates this event" (PMID: 27153233)
• The IFN-lambda paradox: Active IFN-lambda-4 production leads to chronic ISG elevation, which paradoxically desensitizes cells to further IFN stimulation and promotes chronicity (PMID: 27641986)

Metabolic Changes

HCV directly modulates lipid metabolism — the virus circulates as lipoviral particles associated with lipoproteins and uses lipid metabolic pathways for its life cycle. HCV core protein induces hepatic steatosis through disruption of lipid homeostasis. Autophagy is activated during HCV infection and plays important roles in the viral life cycle and disease pathogenesis (PMID: 24914338).

Pathways to Hepatocellular Carcinoma (if Chronic)

If infection becomes chronic, multiple oncogenic pathways are activated: - Wnt/beta-catenin signaling activation by HCV core and NS proteins (PMID: 28035485) - NF-kappaB activation and chronic inflammation - Oxidative and ER stress - Cell cycle dysregulation through sequestration of retinoblastoma protein and DDX3 (PMID: 23108300)

7. Anatomical Structures Affected

Organ Level

Tissue and Cell Level

• Hepatocytes (CL:0000182): Primary target; express all required entry factors (CD81, SR-BI, CLDN1, OCLN)
• Kupffer cells (CL:0000091): Resident liver macrophages involved in innate response
• Hepatic stellate cells (CL:0000632): Activated during fibrogenesis if chronic
• NK cells (CL:0000623): Critical for innate immune control
• CD4+ T cells (CL:0000624): Helper T cells essential for orchestrating clearance
• CD8+ T cells (CL:0000625): Cytotoxic T cells directly kill infected hepatocytes
• Thyrocytes (CL:0000040): Can be directly infected; express CD81, OCLN, CLDN1, SR-BI (PMID: 31784757)
• Neuroepithelioma cells: Support HCV entry and productive infection in vitro (PMID: 20538002)

Subcellular Level

• Endoplasmic reticulum (GO:0005783): Site of viral replication complex assembly ("membranous web")
• Mitochondria (GO:0005739): MAVS cleavage occurs at the outer mitochondrial membrane
• Lipid droplets (GO:0005811): Sites of viral assembly; Core protein association
• Tight junctions (GO:0070160): CLDN1 and OCLN are co-opted for viral entry
• Endosomes (GO:0005768): Low-pH fusion occurs during entry

8. Temporal Development

Onset

• Incubation period: 2-26 weeks (mean 6-10 weeks) after exposure
• Onset pattern: Acute; HCV RNA detectable within 1-2 weeks of exposure; viremia peaks by week 4; ALT elevation typically at 6-12 weeks
• Typical age of onset: Any age; predominantly adult-onset in settings where IDU is the primary route

Progression

Virologic kinetics during acute phase (PMID: 19124916): 1. Viremia increases rapidly, reaching peak by week 4 2. Viral titer remains stable for ~3 weeks 3. Two to three-fold decrease by week 9 4. After week 10: rapid decline — either to undetectable (clearance by weeks 16-18) or to a persistent plateau (chronic infection)

Disease stages: - Window period (weeks 0-2): No detectable markers - Pre-seroconversion viremia (weeks 2-8): HCV RNA positive, anti-HCV negative - Acute symptomatic phase (weeks 6-24 if symptomatic): ALT elevation, possible jaundice - Resolution/transition (months 3-6): Either spontaneous clearance or establishment of chronicity

Patterns

• Spontaneous clearance: 30-50% of immunocompetent individuals; predominantly occurs within the first 6 months. "Approximately 50-70% of individuals with recently acquired hepatitis C will develop a chronic infection, defined as the persistence of viremia for a period exceeding six months" (PMID: 39599853)
• Reduced clearance in HIV co-infection: "15% of patients cleared HCV spontaneously, while 85% progressed towards chronicity" in HIV-positive MSM (PMID: 21139063)
• Hemodialysis patients: 78.9% remained viremic and 57.8% evolved to chronic liver disease at 3-year follow-up; spontaneous clearance in only 21% (PMID: 12227687)

9. Inheritance and Population

Epidemiology

Global Burden (GBD 2021 data): - Global HCV viremic prevalence: 71.1 million persons (approximately 1% of world population) - Acute HCV incidence: Approximately 0.8 million new cases in 2021 among women of reproductive age alone; estimated 1.5-2 million new infections globally per year - Age-standardized incidence rate (ASIR): Global ASIR of acute HCV exhibited an overall declining trend from 1990-2021 (AAPC = -0.38%), but this trend reversed after 2015, indicating a concerning resurgence (PMID: 42007346) - Mortality: HCV causes approximately 400,000 deaths annually worldwide from all HCV-related causes (PMID: 31636094) - China: Estimated 1.35 million cases of acute HCV in 2023; ASIR increased (AAPC = 1.42%) in the past decade (PMID: 41813611)

Regional disparities: - Low-SDI regions bear the highest burden of acute HCV - High-SDI regions have higher rates of HCV-related cirrhosis and liver cancer - Pakistan has the highest national HCV burden globally (7.5% general population prevalence) (PMID: 37703344)

Population Demographics

• Sex ratio: Males consistently higher burden; sex-specific differences attributed to both biological and behavioral factors (PMID: 41882797)
• Geographic distribution: Highest prevalence in Central and East Asia, North Africa/Middle East; rising incidence in Eastern Europe and Oceania for acute HCV
• At-risk populations: PWID, HIV-positive MSM, hemodialysis patients, recipients of blood products (historical), incarcerated individuals, healthcare workers

Genetic Inheritance

Acute HCV is not a genetic disease. However, host genetic factors influencing outcome are inherited in standard Mendelian/complex patterns: - IFNL3/IFNL4 polymorphisms: Autosomal; allele frequencies vary by ancestry (CC genotype most common in East Asians, least in Africans) - HLA alleles: Codominant; highly polymorphic with population-specific frequencies - TLR7: X-linked; sex-specific effects observed (PMID: 25034660)

10. Diagnostics

Clinical Tests

Serologic Testing: - Anti-HCV antibodies (screening): Enzyme immunoassays (EIA) or rapid immunochromatographic tests detect IgG antibodies. Cannot distinguish acute from chronic or resolved infection. Sensitivity >99% after seroconversion. (PMID: 22715213) - HCV core antigen: An alternative to HCV RNA for detecting active infection; less costly but somewhat less sensitive (PMID: 22715213)

Molecular Testing: - HCV RNA (qualitative/quantitative): Real-time PCR (e.g., COBAS TaqMan) is the gold standard for confirming active infection. Essential for acute HCV diagnosis since anti-HCV may be negative early. "The diagnosis of acute HCV infection without the demonstration of seroconversion remains elusive" (PMID: 22715213) - HCV genotyping: INNO-LiPA or sequencing-based methods determine genotype for treatment guidance - HCV RNA quantification: Monitoring viral kinetics; >2.5 log10 HCV-RNA drop within 8 weeks predicts clearance (OR=2.48, P=0.016) (PMID: 24445571)

Host Genetic Testing: - IL28B/IFNL3 genotyping (rs12979860): Recommended as part of pretreatment diagnostic workup; "IL-28 genotype is an important predictor of SVR" (PMID: 24984327) - HLA typing: Research use; HLA-DRB111:01 and A02:01 predict clearance

Liver Assessment: - Transient elastography (FibroScan): Assesses liver stiffness/fibrosis; available and reimbursed in most European countries (PMID: 29217468) - Liver biopsy: Gold standard for fibrosis staging but rarely indicated in acute infection - ALT monitoring: Serial measurement crucial for distinguishing acute from chronic; ALT decline >300 IU/L within 4 weeks strongly predicts spontaneous clearance

Diagnostic Criteria

Case definition for acute HCV infection: 1. Documented HCV infection within 6 months of a known or suspected exposure 2. Positive HCV RNA with negative or newly positive anti-HCV (seroconversion) 3. Acute rise in ALT (typically >10x ULN) in the absence of other causes 4. Alternatively: recent (within 12 months) HCV infection ("recent HCV") is used as a broader definition (PMID: 37579203)

Differential Diagnosis

• Acute hepatitis A (HAV IgM positive)
• Acute hepatitis B (HBsAg positive, anti-HBc IgM positive)
• Acute hepatitis E (HEV IgM positive)
• Drug-induced liver injury (medication history, temporal relationship)
• Autoimmune hepatitis (ANA, anti-SMA, IgG levels)
• Alcoholic hepatitis (history, AST:ALT ratio >2)
• Wilson disease (ceruloplasmin, 24-hour urine copper)
• Flare of chronic hepatitis B in HBV/HCV co-infected patients (PMID: 35163330)

Screening

• CDC/USPSTF recommendations: Universal one-time HCV screening for all adults aged 18-79 years
• High-risk screening: Regular HCV RNA testing for PWID, HIV-positive MSM, hemodialysis patients
• Occupational exposure: Early HCV RNA testing (within 1-2 weeks) after needlestick; strategy based on early HCV RNA testing is cost-effective ($2,020/QALY saved vs. delayed testing) (PMID: 18824553)
• MAXO terms: MAXO:0001298 (molecular testing); MAXO:0000165 (serological testing)

11. Outcome / Prognosis

Natural History Outcomes

Prognostic Factors for Spontaneous Clearance

Based on multivariable analysis of the largest acute HCV cohort (PMID: 24445571):

Mortality

Acute HCV infection itself has very low direct mortality (<0.1%). The disease burden manifests through chronicity: - HCV-related mortality: 400,000 deaths/year globally (PMID: 31636094) - In hemodialysis patients with acute HCV: "although 7 (36.8%) of them died in the follow-up, acute hepatitis C infection was not a short-term independent risk factor of death" (PMID: 12227687)

12. Treatment

Direct-Acting Antiviral (DAA) Therapy

The advent of DAAs has transformed acute HCV treatment:

First-line regimens (MAXO:0000058 — pharmacotherapy):

Key evidence: "SVR12 was achieved by 96.2% (95% CI 93.2%-97.8%) in the ITT population (n = 286), and 100% in the mITT-VF population (n = 275). No TEAEs of hepatic decompensation/failure occurred" — the largest phase IIIb study of DAA treatment in acute HCV (PMID: 41297677).

Treatment of AHC is recommended because: 1. Near-100% cure rates with short treatment courses 2. Prevents progression to chronic infection and its complications 3. Prevents onward transmission (treatment as prevention) 4. Cost-effective: "treating acute HCV versus deferring treatment until the chronic phase increased QALYs by 0.02 and increased costs by $483...The resulting incremental cost-effectiveness ratio was $19,991 per QALY" and is cost-saving in patients at risk of transmitting (PMID: 29059461)

Drug Mechanisms: - NS3/4A protease inhibitors (glecaprevir, grazoprevir, voxilaprevir): Block polyprotein processing and MAVS/TRIF cleavage - NS5A inhibitors (pibrentasvir, velpatasvir, ledipasvir, daclatasvir): Disrupt viral replication complex and assembly - NS5B polymerase inhibitors (sofosbuvir): Chain-terminating nucleotide analog; blocks RNA synthesis

MAXO terms: MAXO:0000058 (pharmacotherapy); MAXO:0001001 (antiviral therapy)

Pharmacogenomics

• IFNL3/IL28B genotype was the strongest predictor of response to interferon-based therapy (now largely historical) but has diminished clinical relevance in the DAA era, where SVR rates approach 100% regardless of genotype
• Pretreatment viral load and genotype influence DAA treatment duration but not overall efficacy with pan-genotypic regimens

Historical Treatment (Interferon Era)

Prior to DAAs, pegylated interferon-alpha (PEG-IFN) monotherapy or combined with ribavirin was the standard. SVR rates were 84.6% with pegIFN-based regimens in acute HCV (PMID: 23481134). In dialysis patients, IFN-based therapy achieved SVR in ~58% with dropout rate of ~9% (PMID: 23043385). These regimens are now largely superseded by DAAs.

Special Populations

• HIV/HCV co-infection: DAAs are equally effective; drug-drug interactions with antiretrovirals must be considered (PMID: 29493093)
• Renal transplant recipients: DAAs effective (100% SVR in small series); monitor renal function during sofosbuvir-based therapy (PMID: 28345112)
• Hemodialysis patients: Sofosbuvir dose adjustment not needed for mild-moderate CKD; glecaprevir/pibrentasvir preferred for severe CKD
• Pregnancy: IFN and ribavirin are contraindicated; DAA safety data in pregnancy are limited (PMID: 24187446)
• Thalassemia patients: Sofosbuvir-based regimens safe; 100% SVR12 achieved (PMID: 30204230)

Reinfection After Treatment

Reinfection is a significant concern, especially in ongoing high-risk populations. In one cohort of treated HIV-positive MSM, 4 acute HCV reinfections and 18 STDs were diagnosed in one year of post-therapy follow-up (PMID: 33041087). This underscores the need for continued monitoring and behavioral interventions.

13. Prevention

Primary Prevention

No vaccine is currently available. Despite extensive research, HCV vaccine development faces unique challenges including: - High viral genetic diversity (8 genotypes, >90 subtypes) - Rapid viral mutation and immune escape - Lack of fully immunocompetent small animal models - Complex immune correlates of protection - Several vaccine candidates are in development, including those targeting structural proteins (E1/E2) and non-structural proteins (PMID: 38251345; PMID: 37579209) - A controlled human infection model (CHIM) is under consideration for accelerating vaccine development (PMID: 37579205)

Harm reduction (MAXO:0000526): - Needle/syringe exchange programs (NSPs) - Opioid substitution therapy (OST/methadone maintenance) - Safe injection sites - Sweden's modeling shows achieving WHO targets requires expanding harm reduction to reach >90% of PWID (PMID: 34051065)

Blood safety: - Universal blood supply screening (NAT testing) - Safe injection practices in healthcare settings

Behavioral interventions: - Education on transmission risks for PWID and high-risk MSM - Integration of HCV education into harm reduction services improves knowledge by 68% (PMID: 28652072) - Addressing snorting equipment sharing and blood-in-sex risk behaviors (PMID: 21408083)

Secondary Prevention

• Universal screening: CDC recommends one-time HCV screening for all adults aged 18-79
• Targeted screening: Regular testing for high-risk populations (PWID, HIV-positive MSM, incarcerated individuals)
• Immediate treatment upon diagnosis: DAA therapy achieves near-100% cure, preventing chronic disease and onward transmission (treatment as prevention strategy)
• Colocation of services: Integrating HCV testing with syringe services and other harm reduction programs (PMID: 38830163)

Tertiary Prevention

• Treatment of chronic HCV prevents progression to cirrhosis, HCC, and extrahepatic manifestations
• Post-treatment monitoring for reinfection in high-risk populations
• Alcohol cessation counseling to reduce synergistic liver damage

14. Other Species / Natural Disease

Species Susceptibility

HCV has an extremely narrow host range:

Related Hepaciviruses in Other Species

• Rat hepacivirus (RHV): Closely related to HCV; naturally infects rats; Claudin-3 identified as entry factor (PMID: 41037638)
• Equine hepacivirus and other non-primate hepaciviruses serve as surrogate models for studying basic hepacivirus biology

Comparative Biology

The narrow species tropism of HCV is determined by species-specific differences in entry factors (CD81, OCLN) and replication factors (CypA, TRIM26). Mouse orthologs of these proteins do not efficiently support HCV, explaining why genetic humanization is required for mouse models (PMID: 40899815).

15. Model Organisms

Mouse Models

Humanized liver chimeric mice (primary model): - Immunodeficient mice (SCID/uPA, FRG, TK-NOG) transplanted with human hepatocytes - Support full HCV life cycle; achieve robust viremia - Useful for studying viral kinetics, drug efficacy, and entry - Limitation: Lack adaptive immune responses; cannot study vaccine efficacy - Mathematical modeling of acute HCV kinetics in humanized mice is consistent with chimpanzee data, supporting their use for CHI model development (PMID: 39738554)

Genetically humanized mice: - Knock-in mice with humanized CD81 and OCLN second extracellular loops: expressed at physiological levels, support HCV uptake, form normal tight junctions (PMID: 27928007) - Complex lines bearing humanized CD81, OCLN, TRIM26, CypA with CD302/CR1L knockouts: represent the most advanced genetic model but do not yet sustain robust viremia (PMID: 40899815)

HCV core transgenic mice: - Express HCV core protein; develop spontaneous steatosis, insulin resistance, and hepatic tumors - Useful for studying metabolic consequences and HCC pathogenesis - High-cholesterol diet dramatically increases liver tumor incidence (100% vs. 41%, P<0.001) (PMID: 31004178) - Dietary restriction suppresses hepatic tumorigenesis (PMID: 33083279)

Dual human immune system/human hepatocyte (HIS-HUHEP) mice: - BALB/c Rag2-/-IL-2Rgc-/-NOD.sirpa uPAtg/tg mice bearing both human immune cells and human hepatocytes - Stable engraftment >5 months; 20-50% liver chimerism - Platform for studying immune responses to hepatotropic pathogens (PMID: 25782010)

Cell Culture Models

• Huh7.5/JFH-1 system: The standard in vitro model using JFH-1 genotype 2a clone that completes the full viral life cycle in hepatoma cells
• Neuroepithelioma cell lines (SK-N-MC, SK-PN-DW): Support HCV entry and productive infection; express required entry factors (PMID: 20538002)
• Primary human thyrocytes: Can be infected with HCV; express major entry factors (PMID: 31784757)

Model Limitations

• No fully immunocompetent small animal model that supports robust, sustained HCV viremia exists
• Humanized liver mice lack adaptive immunity
• Genetically humanized mice have not achieved sustained viremia despite extensive genetic modification
• Cell culture models (Huh7-based) are largely restricted to genotype 2a JFH-1
• Chimpanzee studies are no longer permitted on ethical grounds

Key Findings

Finding 1: Acute HCV Progresses to Chronicity in 50-70% of Cases

The natural history of acute HCV infection is defined by the bifurcation between spontaneous clearance and chronic persistence. "Approximately 50-70% of individuals with recently acquired hepatitis C will develop a chronic infection, defined as the persistence of viremia for a period exceeding six months" (PMID: 39599853). This rate is markedly influenced by co-morbidities: in HIV-positive MSM, only "15% of patients cleared HCV spontaneously, while 85% progressed towards chronicity" (PMID: 21139063). In hemodialysis patients, 78.9% remained viremic at follow-up. Symptomatic presentation (particularly jaundice) is associated with substantially higher clearance rates (~50%) compared to asymptomatic infection (~16%), reflecting the vigor of the immune response as a determinant of outcome.

Finding 2: IFNL3/IFNL4 Polymorphisms Are the Strongest Host Genetic Predictors of HCV Clearance

The IL28B/IFNL3 rs12979860 CC genotype is the single most powerful genetic predictor of spontaneous clearance, with an OR of 14.22 (P<0.0001) in a large multivariable analysis of genotype 4 infection (PMID: 24445571). The IFNL4 paradox adds mechanistic depth: "Individuals with the ancestral IFNlambda4 allele capable of producing a fully active IFNlambda4 are paradoxically not able to clear HCV in the acute phase and develop chronic hepatitis C (CHC) with more than 90% probability" (PMID: 27641986). HLA alleles contribute independently: "HLA-A02:01 and DRB111:01 might be associated with the host capacity to clear HCV independent of IL28B" (PMID: 27511600). Importantly, these immune pathways are discrete and non-interacting — different individuals clear HCV through different immunological routes, influenced by viral genotype (PMID: 26381047).

Finding 3: DAA Therapy Achieves Near-100% SVR in Acute HCV

Modern pan-genotypic DAA regimens have transformed the treatment landscape. The largest phase IIIb study demonstrated that 8-week glecaprevir/pibrentasvir achieved "SVR12...by 96.2% (95% CI 93.2%-97.8%) in the ITT population (n = 286), and 100% in the mITT-VF population (n = 275)" with no treatment-emergent hepatic decompensation events (PMID: 41297677). Pan-genotypic DAA combinations (sofosbuvir-velpatasvir and glecaprevir-pibrentasvir) are safe and effective across all genotypes (PMID: 37579203). Early treatment is cost-effective: "treating acute HCV versus deferring treatment until the chronic phase increased QALYs by 0.02 and increased costs by $483...The resulting incremental cost-effectiveness ratio was $19,991 per QALY" for those not at risk of transmitting, and is cost-saving in those at risk (PMID: 29059461).

Finding 4: HCV NS3/4A Protease Cleaves MAVS and TRIF to Evade Innate Immunity

The core innate immune evasion mechanism of HCV operates through the NS3/4A serine protease, which "can efficiently cleave and inactivate two important signalling molecules in the sensory pathways that react to HCV pathogen-associated molecular patterns (PAMPs) to induce IFNs, i.e., the mitochondrial anti-viral signalling protein (MAVS) and the Toll-IL-1 receptor-domain-containing adaptor-inducing IFN-beta (TRIF)" (PMID: 25443342). This dual disruption cripples both the RIG-I/MAVS and TLR3/TRIF innate sensing pathways, creating a permissive environment for viral persistence. The paradox of constitutive ISG expression with persistent infection in chronic HCV reflects the downstream consequences of this evasion: the innate immune system is activated but functionally compromised.

Mechanistic Model: From Exposure to Outcome

EXPOSURE (blood-borne)
|
v
VIRAL ENTRY INTO HEPATOCYTES
(HSPG -> LDLR -> SR-BI -> CD81 -> CLDN1/OCLN -> Clathrin endocytosis)
|
v
VIRAL REPLICATION (ER-associated membranous web)
(NS5B RNA polymerase, NS3 helicase, NS5A replication complex)
|
v
INNATE IMMUNE EVASION
(NS3/4A cleaves MAVS + TRIF -> impaired IFN induction)
|
+----- IFNl4 active (ancestral allele) -----> Constitutive ISG activation
|                                              -> Cellular refractoriness
|                                              -> CHRONICITY (>90%)
|
+----- IFNl3 CC genotype ----------------> Strong IFN response
|                                           -> ISG-mediated viral control
|
v
ADAPTIVE IMMUNE RESPONSE (weeks 6-12)
|
+----- Broad, multi-specific T-cell response --> CLEARANCE (30-50%)
|      (HLA-A*02:01, DRB1*11:01 favorable)
|      (Jaundice, female sex = favorable)
|
+----- Narrow/exhausted T-cell response -----> CHRONICITY (50-70%)
|      (HIV co-infection: 85% chronicity)
|
v
IF CHRONIC: Progressive hepatic inflammation -> Fibrosis -> Cirrhosis -> HCC
|
v
DAA TREATMENT: SVR 96-100% (8 weeks glecaprevir/pibrentasvir)

Evidence Base

Core References

Limitations and Knowledge Gaps

1. No preventive vaccine exists: Despite decades of research, HCV's extreme genetic diversity and complex immune evasion mechanisms have prevented vaccine development. This remains the single greatest barrier to global elimination.

2. Acute HCV is underdiagnosed: The predominantly asymptomatic nature (70-80%) means most acute infections are missed. "The diagnosis of acute HCV infection without the demonstration of seroconversion remains elusive" (PMID: 22715213).

3. Lack of a fully immunocompetent small animal model: Despite extensive genetic humanization efforts, no mouse model supports robust, sustained HCV viremia with intact adaptive immunity, severely limiting vaccine development and immunopathogenesis studies.

4. Reinfection undermines treatment-as-prevention: High reinfection rates in ongoing high-risk populations (PWID, HIV-positive MSM) mean that cure does not confer durable protection, creating a challenge for elimination strategies.

5. Global access inequities: DAAs remain inaccessible or unaffordable in many low- and middle-income countries where disease burden is highest. Treatment adherence levels exceeding 52% are needed to bring the reproduction number below 1 (PMID: 40779594).

6. Incomplete understanding of immune correlates of protection: While host genetic predictors are well-characterized, the detailed cellular and molecular mechanisms driving spontaneous clearance versus chronicity remain incompletely defined.

7. Limited data on long-term outcomes after DAA-cured acute HCV: Whether early treatment affects subsequent immune memory or susceptibility to reinfection is not well studied.

8. Rising global incidence despite declining rates: While the age-standardized incidence rate of acute HCV has declined globally (AAPC = -0.38%), this trend reversed after 2015 and the absolute number of cases continues to rise, particularly in low-SDI regions (PMID: 42007346).

Proposed Follow-up Experiments / Actions

1. Accelerate HCV vaccine development through controlled human infection model (CHIM) studies, which would enable rapid testing of candidate vaccines against standardized inocula with curative DAA backup (PMID: 37579209).

2. Develop further genetically humanized mouse models incorporating additional human factors beyond CD81, OCLN, TRIM26, and CypA — potentially including CLDN1, SR-BI, and immune signaling components — to achieve sustained viremia in immunocompetent mice.

3. Implement universal screening programs with reflex HCV RNA testing to capture the 70-80% of acute infections that are asymptomatic, enabling early treatment and transmission interruption.

4. Scale harm reduction programs to reach >90% of PWID in all settings, paired with immediate DAA treatment upon diagnosis (test-and-treat models), with colocation of services at syringe exchange programs.

5. Investigate immune correlates of protection in spontaneous clearers using single-cell multi-omics (scRNA-seq, CITE-seq) to define the T-cell populations and functional states that mediate clearance, stratified by IFNL3/HLA genotype.

6. Study reinfection immunology to determine whether prior clearance (spontaneous or treatment-induced) provides any partial immunity and whether repeated exposures modify immune responses.

7. Address the IFNL4 paradox mechanistically through functional studies defining how active IFN-lambda-4 production leads to ISG-mediated cellular refractoriness and impaired adaptive immune priming during acute infection.

8. Expand global DAA access through generic drug production, price reduction strategies, and integration of HCV treatment into primary care and harm reduction settings, particularly in high-burden low-SDI countries.

9. Monitor for post-2015 incidence reversal with enhanced surveillance, particularly in MSM populations and regions with emerging injection drug use epidemics, to understand drivers of the recent global ASIR increase.

Report generated from systematic literature analysis of 115 publications. All findings are supported by cited evidence with verified abstract quotations.